BioCentury | Jun 10, 2013
Clinical News

Sefelsa gabapentin GR regulatory update

...neuralgia (PHN) and Zipsor diclofenac potassium to treat pain. Last November, the company reported that DM-1992...
BioCentury | Nov 12, 2012
Finance

Highlights of weekly biotech stock moves

...dropped $1.03 (70%) to $0.44. Depomed Inc. (NASDAQ:DEPO) gained $0.06 to $5.71 last week after DM-1992...
BioCentury | Nov 12, 2012
Clinical News

DM-1992: Phase II data

...U.S. Phase II trial in 34 advanced PD patients with motor fluctuations showed that twice-daily DM-1992...
...day 10 vs. generic immediate-release (IR) carbidopa-levodopa dosed as needed (4.5 vs. 5.5 hours/day). Specifically, DM-1992...
...is considering partnering DM-1992 while monitoring "competitive developments." Depomed Inc. (NASDAQ:DEPO), Menlo Park, Calif. Product: DM-1992...
BioCentury | Nov 8, 2012
Clinical News

Depomed's DM-1992 meets Phase II Parkinson's endpoint

...Depomed Inc. (NASDAQ:DEPO) said twice-daily DM-1992 met the primary endpoint vs. generic immediate-release (IR) carbidopa-levodopa dosed...
...needed (average of 4.8 doses/day) in a Phase II trial to treat Parkinson's disease (PD). DM-1992...
...will continue to evaluate the data and is considering partnering DM-1992 while monitoring "competitive developments." DM-1992...
BioCentury | Jan 30, 2012
Clinical News

DM-1992: Phase II started

...Depomed began an open-label, crossover, U.S. Phase II trial to compare twice-daily oral DM-1992 vs. immediate-release...
...up to 45 PD patients with motor fluctuations. Depomed Inc. (NASDAQ:DEPO), Menlo Park, Calif. Product: DM-1992...
BioCentury | Feb 14, 2011
Clinical News

DM-1992: Phase I data

...Phase I trial in 16 patients with stable PD showed that 2 formulations of twice-daily DM-1992...
...NYSE:BMY, New York, N.Y.) was the active comparator. Depomed Inc. (NASDAQ:DEPO), Menlo Park, Calif. Product: DM-1992...
BioCentury | Aug 17, 2009
Clinical News

DM-1992: Phase I data

...Russian Phase I trial in 18 patients showed that 1 of 2 formulations of oral DM-1992...
...hours for the comparator. DM-1992 was well tolerated. Depomed Inc. (NASDAQ:DEPO), Menlo Park, Calif. Product: DM-1992...
BioCentury | Feb 23, 2009
Clinical News

DM-1992: Phase I started

...open-label, crossover, Russian Phase I trial in 18 patients to compare 2 formulations of oral DM-1992...
...from Bristol-Myers Squibb Co. (NYSE:BMY, New York, N.Y.). Depomed Inc. (NASDAQ:DEPO), Menlo Park, Calif. Product: DM-1992...
Items per page:
1 - 8 of 8